Literature DB >> 1683495

Recombinant toxins for cancer treatment.

I Pastan1, D FitzGerald.   

Abstract

Recombinant toxins target cell surface receptors and antigens on tumor cells. They kill by mechanisms different from conventional chemotherapy, so that cross resistance to conventional chemotherapeutic agents should not be a problem. Furthermore, they are not mutagens and should not induce secondary malignancies or accelerate progression of benign malignancies. They can be mass-produced cheaply in bacteria as homogeneous proteins. Either growth factor-toxin fusions or antibody-toxin fusions can be chosen, depending on the cellular target.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1683495     DOI： 10.1126/science.1683495

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   63.714


  50 in total

Review 1.  Targeted kill: from umbrellas to monoclonal antibodies.

Authors:  V S Byers; R W Baldwin
Journal:  J Clin Immunol       Date:  1992-11       Impact factor: 8.317

2.  An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells.

Authors:  Patrick P Ng; Jay S Dela Cruz; David N Sorour; James M Stinebaugh; Seung-Uon Shin; Daniel S Shin; Sherie L Morrison; Manuel L Penichet
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

3.  Effect of fibroblast growth factor saporin mitotoxins on human bladder cell lines.

Authors:  T A Tetzke; M C Caton; P A Maher; Z Parandoosh
Journal:  Clin Exp Metastasis       Date:  1997-11       Impact factor: 5.150

Review 4.  Insulin-like growth factors in central nervous system tumors.

Authors:  R P Glick; T Lichtor; T G Unterman
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

5.  Compatible-solute-supported periplasmic expression of functional recombinant proteins under stress conditions.

Authors:  S Barth; M Huhn; B Matthey; A Klimka; E A Galinski; A Engert
Journal:  Appl Environ Microbiol       Date:  2000-04       Impact factor: 4.792

Review 6.  Signal transduction pathways: new targets in oncology.

Authors:  R K Sweeb; J H Beijnen
Journal:  Pharm World Sci       Date:  1993-12-17

7.  Eradication of tumor colonization and invasion by a B cell-specific immunotoxin in a murine model for human primary intraocular lymphoma.

Authors:  Zhuqing Li; Sankaranarayana P Mahesh; De Fen Shen; Baoying Liu; Willie O Siu; Frank S Hwang; Qing-Chen Wang; Chi-Chao Chan; Ira Pastan; Robert B Nussenblatt
Journal:  Cancer Res       Date:  2006-11-01       Impact factor: 12.701

Review 8.  Preclinical testing of an anti-erbB-2 recombinant toxin.

Authors:  C R King; P G Kasprzyk; P H Fischer; R E Bird; N A Turner
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

9.  Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature.

Authors:  F J Burrows; P E Thorpe
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-01       Impact factor: 11.205

10.  Cytosine arabinoside increases the binding of 125I-labelled epidermal growth factor and 125I-transferrin and enhances the in vitro targeting of human tumour cells with anti-(growth factor receptor) mAb.

Authors:  M Caraglia; P Tagliaferri; P Correale; G Genua; A Pinto; S Del Vecchio; G Esposito; A R Bianco
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.